MarginsXMarginsX
Home › Markets › Health Care › REVB

Revelation Biosciences Inc. (REVB)

REVB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.82
-10.43% on the day
Market cap
$2.6M
Nano cap
Revenue
No annual revenue in SEC XBRL data for this filer
Net income
No annual revenue in SEC XBRL data for this filer

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerREVB on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001810560
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

No annual revenue in SEC XBRL data for this filer.

Warning signs

Cash runway
10.8 months
$9.1M cash at September 30, 2026
Share count, 1 year
+223.0%
2025-11-04 to 2026-11-02 · +437490.2% over 3 years
Going-concern doubt
Yes
10-Q filed November 5, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"The Company does not anticipate that its current cash and cash equivalents balance will be sufficient to sustain operations within one year after the date that the Company's unaudited condensed financial statements for September 30, 2026 were issued, which raises substantial doubt about its ability to continue as a going concern."
10-Q 2026-11-05
Cash and burn$9.1M cash; operating cash flow -$2.5M a quarter.Report 2026-09-30
Shares outstanding683,442 (2026-11-02); 5,924,137 a year earlier; 6,297,303 three years earlier. 1y figure adjusted for splits (1-for-28 overall); 3y figure adjusted for splits (1-for-40320 overall).Cover page 2026-11-02
Reverse splits, 3 years5; latest 1-for-7 on 2026-10-20Source 2026-10-20
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-01-30
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBaker Tilly US, LLP, San Diego, California, United StatesPCAOB Form AP 2026-03-31
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$3.3M-$2.4M$9.1MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2026
2026-06-30
Not filed-$3.3M-$2.6M$11.5MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2026
2026-03-31
Not filed-$3.0M-$3.2M$14.1MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2025
2025-12-31
Not filed-$2.5M-$2.0M$10.7MNo debt tagsNeeds four quarters10-K 2026-02-26
Q3 2025
2025-09-30
Not filed-$1.9M-$1.6M$12.7MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2025
2025-06-30
Not filed-$2.4M-$1.9M$5.2MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2025
2025-03-31
Not filed-$2.1M-$2.8M$3.7MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2024
2024-12-31
Not filed-$1.7M-$3.7M$6.5MNo debt tagsNeeds four quarters10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-02-11
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-13
Latest proxyDEF 14A2026-05-11

Source: SEC EDGAR submissions feed, 390 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+9.6%
1 month-16.5%
3 months-45.1%
Year to date+33.3%
1 year+16.9%
From 52-week high-83.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Other listings for this company

TickerNamePrice
REVBWRevelation Biosciences Inc. Warrant$0.0033

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
EOCNEocene Ltd.$2.53+5.86%$2.6M
GNPXGenprex Inc.$1.90-8.65%$2.5M
PPBTPurple Biotech Ltd.$1.68+3.70%$2.7M
PRFXPRF Technologies Ltd.$0.6948-11.22%$2.4M
ERNAErnexa Therapeutics Inc.$1.69+0.60%$2.9M
DRMADermata Therapeutics Inc.$0.5985-3.65%$3.0M
NRSNNeuroSense Therapeutics Ltd.$1.56-7.40%$3.0M
MBIOMustang Bio Inc.$0.3947-6.34%$3.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier